Owing to its high specificity and affinity for AFP antigen in hepatic cancer cells, anti-AFP monoclonal antibody (antiAFPMcAb) can carry various “warheads” such as chemotherapy agents, radionuclides, or toxins to selectively attack AFP-positive cancer cells [21–23]. Here, AFP is linked to cancer.